The Rogosin Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: New York City NY United States (1983)

Organization Overview

First Clinical Trial
2003
NCT00146237
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Rogosin Institute | The Rogosin Institute

Active Ingredients

Drugs in Phase 4 Trials (3)

bortezomib (velcade) (2 trials)

patiromer (veltassa) (1 trial)

phenytoin (mesantoin) (2 trials)

Drugs in Phase 2 Trials (2)

buprenorphine (1 trial)

docetaxel (taxotere) (1 trial)

Drugs in Phase 1 Trials (3)

glucose (3 trials)

megestrol (megace) (1 trial)

nevulose (1 trial)

Drugs in Other Trials (3)

aliskiren (tekturna) (1 trial)

fructose (2 trials)

metoprolol (lopressor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 1)

Chronic Pain (Phase 2)

Cognitive Dysfunction (Phase 1)

Colorectal Neoplasms (Phase 2)

Depression (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Hematuria (Phase 4)

Hyperkalemia (Phase 4)

Hypertriglyceridemia (Phase 1)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 2)

Lupus Nephritis (Phase 4)

Nephritis (Phase 4)

Opioid-Related Disorders (Phase 2)

Overweight (Phase 1)

Proteinuria (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 11